Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28067236 | 0.83 | HDAC3 (0.79) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL24968639 | 0.82 | HDAC6 (0.59) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL28248201 | 0.82 | HDAC6 (0.62) | HDAC6HDAC3HDAC1HDAC2SLC6A4 | |
| SCHEMBL30145542 | 0.82 | HDAC6 (0.62) | HDAC6HDAC3HDAC1HDAC2SLC6A4 | |
| SCHEMBL16266642 | 0.81 | HDAC3 (0.69) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL16646752 | 0.81 | HDAC6 (0.63) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL29412232 | 0.81 | HDAC3 (1.00) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL21128025 | 0.81 | HDAC6 (0.66) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL4729593 | 0.81 | HDAC3 (1.00) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL24968663 | 0.80 | HDAC3 (0.53) | HDAC6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017214565-A1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC., (US) | 2017-12-14 | — | — | WO | disclosed |